Advertisement

Topics

Clovis Oncology: Revisiting After ARIEL3 Success

12:32 EDT 4 Aug 2017 | Topix

Wall Street's negative reaction to Bristol-Myers Squibb collaboration appears overdone, as the takeout thesis still appears on the table. Shares of Clovis Oncology have risen around 40% since highlighting the stock in January, when I noted that ovarian cancer was just the beginning of the franchise management is trying to build around PARP inhibitor Rubraca.

Original Article: Clovis Oncology: Revisiting After ARIEL3 Success

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology: Revisiting After ARIEL3 Success"

Quick Search
Advertisement